Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Clin Cancer Res. 2017 Mar 9;23(15):4146–4154. doi: 10.1158/1078-0432.CCR-16-3138

Figure 1.

Figure 1

Clinical efficacy of the FOLFOX + cetuximab + dasatinib treatment. A) Waterfall plot of best response for the regimen in the Phase IB study demonstrates 6 patients with a RECIST response. An additional 7 patients had tumor regression that did not meet RECIST criteria for response. Patients with progressive disease noted by new lesions are listed as +30% growth. B) Waterfall plot of patients in the Phase II study treated with dasatinib, FOLFOX, with or without cetuximab, measuring the maximum change from baseline in the sum of the longest diameter for target lesions.